BOSTON SCIENTIFIC CORPORATION Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2025-03-19: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo; Period 2024-01-01..2024-12-31; Value $0.00.
- 2025-03-19: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo; Period 2023-01-01..2023-12-31; Value $0.00.
- 2025-03-19: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo; Period 2022-01-01..2022-12-31; Value -$92.81K.
- 2025-03-19: Disclosure Adjustment To Compensation; Qualifiers AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo; Period 2021-01-01..2021-12-31; Value -$221.59K.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2025-03-19 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2025-03-19 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2025-03-19 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$92.81K |
| 2025-03-19 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$221.59K |
| 2025-03-19 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $0.00 |
| 2025-03-19 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $9.66M |
| 2025-03-19 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $4.26M |
| 2025-03-19 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $1.10M |
| 2025-03-19 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $1.07M |
| 2025-03-19 DEF 14A | Adjustment To Compensation | ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | -$4.15M |
| 2025-03-19 DEF 14A | Peer Group Issuers Footnote | 2024-01-01..2024-12-31 | We selected the Standard & Poor (S&P) 500 Health Care Index (referred to herein as the “Health Care Index”) as our peer group for purposes of this disclosure, which was comprised o f 61-64 companies for the years 2020 through 2024 included in the S&P 500 that are classified a… | |
| 2025-03-19 DEF 14A | Non Gaap Measure Description | Measure: 1 | 2024-01-01..2024-12-31 | Adjusted Net Sales represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link CAP to our NEOs, including our CEO, for the most recently completed fiscal year to the Company’s performance. Adjusted Net Sales is… |
| 2025-03-19 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2024-01-01..2024-12-31 | The graph below shows the relationship between (i) the four-year total return to stockholders on our common stock and the return on the Health Care Index, in each case assuming $100 was invested in our common stock and in the Health Care Index on December 31, 2020 and that any dividends were reinves… | |
| 2025-03-19 DEF 14A | Compensation Actually Paid Vs Net Income | 2024-01-01..2024-12-31 | The graph below shows the relationship between our net income and the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of 2020 through 2024. Relationship Between Compensation Actually Paid and Net Income | |
| 2025-03-19 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2024-01-01..2024-12-31 | The graph below shows the relationship between our Adjusted Net Sales and the CAP for our CEO/PEO and the average CAP for our non-PEO NEOs for each of 2020 through 2024. Relationship Between Compensation Actually Paid and Adjusted Net Sales | |
| 2025-03-19 DEF 14A | Tabular List Table | 2024-01-01..2024-12-31 | Adjusted Net Sales* Adjusted EPS* Adjusted Operating Income Margin* Organic Net Sales Growth* Relative Total Shareholder Return | |
| 2025-03-19 DEF 14A | Additional402v Disclosure | 2024-01-01..2024-12-31 | * Adjusted Net Sales, Adjusted EPS, Adjusted Operating Income Margin and Organic Net Sales Growth are not prepared in accordance with GAAP. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures and insight into how these non-GAAP financial … | |
| 2025-02-18 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-02-18 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-02-18 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |